Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 11.6% during mid-day trading on Thursday . The stock traded as high as C$0.24 and last traded at C$0.24. 42,371 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 573,681 shares. The stock had previously closed at C$0.22.
Hemostemix Price Performance
The business has a 50 day moving average of C$0.10 and a 200 day moving average of C$0.08. The firm has a market capitalization of C$23.52 million, a price-to-earnings ratio of -13.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- How to Short a Stock in 5 Easy Steps
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Ride Out The Recession With These Dividend Kings
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
